This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The following model input parameters were derived from published primary studies: the proportion of incident TB that is multidrug resistant; the annual incidence of TB; the prevalence of multidrug-resistant TB; the prevalence of non multidrug-resistant TB; the percentage of patients with TB who were treated; the percentage of patients who were alive, and the percentage of patients who were cured for multidrug-resistant and non multidrug-resistant TB; the percentage of patients who were alive and the percentage of patients who were cured if TB was not treated; and the percentage of patients with prevalence multidrug-resistant and non multidrug-resistant TB following treatment and no treatment.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
MEDLINE and global reports published by the World Health Organization were searched for primary studies and relevant data.
Criteria used to ensure the validity of primary studies
Peer-reviewed articles and World Health Organization reports were included in the review. Whenever possible, studies conducted in the developing world were used. Studies evaluating the effectiveness of DOTS-plus that included surgical management were excluded to maintain comparability with studies evaluating the effectiveness of DOTS.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The model input parameters were identified from 13 studies.
Methods of combining primary studies
Where more than one estimate of a model parameter was found, the mean value was used.
Investigation of differences between primary studies
Results of the review
The following model input parameters were derived from published primary studies: 
Methods used to derive estimates of effectiveness
Authors' assumptions were used to obtain some of the estimates of effectiveness.
Estimates of effectiveness and key assumptions
Patients with prevalence multidrug-resistant TB had a lower chance of cure without specific treatment than other untreated patients (e.g. 10% versus 20%);
Patients with highly drug-resistant TB treated with DOTS-plus were less likely to be cured and to survive than patients with multidrug-resistant TB treated with DOTS-plus.
Patient treated under DOTS-plus received second-line agents and could, therefore, develop resistance to these drugs, whereas patients treated under DOTS were assumed not to.
Measure of benefits used in the economic analysis
The measure of health benefit used was the number of TB deaths averted. This information was taken from the model (described above).
Direct costs
This economic analysis assessed the marginal costs of the health care provider. The paper did not provide a breakdown of the individual costs included in the estimates of total marginal costs. However, it did report that the costs of medicine, medical personnel and laboratory costs were included. No breakdown of the resource use and unit costs was provided. Estimates of resource use and costs were taken from published studies. Marginal cost estimates from India were used. No price year was reported. The paper did not indicate whether the future costs were discounted.
